Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

This study is examining how the immune system responds when people with ocular melanoma (a rare eye cancer) that has spread to the liver undergo a procedure called percutaneous hepatic perfusion (PHP) with melphalan — a targeted chemotherapy delivered directly to the liver through blood vessels. **You may be eligible if...** - You have uveal (eye) melanoma that has spread to the liver - Your doctor has determined you are a good candidate for the PHP procedure - You are over 18 years old - You have at least one liver tumor that is 1 cm or larger and can be biopsied - Your life expectancy is more than a few months **You may NOT be eligible if...** - Your cancer has spread significantly outside the liver to other organs - You have serious heart, lung, kidney, or liver function problems - You are pregnant - You have had recent major surgery or an active serious infection Talk to your doctor to see if this trial is right for you.